CGRP Forum
Send to a colleague
Register
Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

News from CGRP Fourm

Atogepant significantly reduced monthly migraine/probable migraine headache days in Phase 2b/3 study

Atogepant, the oral CGRP receptor antagonist being developed for migraine prevention by Allergan, has been shown to significantly reduce monthly migraine/probable migraine (MPM) headache days from baseline, compared to placebo. This primary endpoint of the 12-week Phase 2b/3 study (CGP-MD-01) in patients with episodic migraine was met for all doses and dose regimens of atogepant.

Read the full report here »

Phase 3 HALO data on fremanezumab in episodic migraine published in JAMA

Phase 3 HALO data demonstrating the efficacy of fremanezumab in patients with episodic migraine have been published in the Journal of the American Medical Association (JAMA). Compared to placebo, monthly fremanezumab reduced mean monthly migraine days by 1.5 days over a 12-week period, and a 1.3 day reduction was seen with single higher-dose treatment (p<0.001 for both doses). The most common adverse events that led to discontinuation were injection site erythema (n=3), injection site induration (n=2), diarrhoea (n=2), anxiety (n=2) and depression (n=2).

Read the full report here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Amgen Novartis
© Copyright CGRP Forum 2018. Please click here to unsubscribe from future mailings.
‚Äč